Metagenomi CEO to Speak at Wells Fargo Healthcare Conference
Metagenomi Therapeutics will present at the Wells Fargo 21st Annual Healthcare Conference via a fireside chat made available on its investor site. The company focuses on in vivo genome editing and highlights MGX-001 for hemophilia A, describing a preclinical profile with targeted genome editing and durable gene expression.